Skittish investors seemed more worried than analysts about word from Halozyme Therapeutics Inc. and Viropharma Inc. that the Phase II study will be discontinued with subcutaneous Cinryze (C1 esterase inhibitor with recombinant hyaluronidase [rHuPH20]) for hereditary angioedema (HAE) because of high levels of non-neutralizing antibodies.